Cinqair or Cinqaero Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The growth in the historic period can be attributed to limitations of corticosteroid therapies, identification of eosinophilic asthma phenotypes, clinical success of il 5 inhibitors, growth of biologic adoption, specialist driven treatment protocols.

The growth in the forecast period can be attributed to increasing asthma prevalence, personalized respiratory care approaches, expansion of biologic reimbursement, improved patient stratification, growing pulmonology specialty networks. Major trends in the forecast period include growth of targeted biologics for severe asthma, shift toward il 5 inhibitor therapies, rising diagnosis of eosinophilic asthma, expansion of hospital based infusion treatments, focus on reducing asthma exacerbations.

Increasing air pollution is expected to drive the growth of the Cinqair (Cinqaero) market in the coming years. Air pollution involves the contamination of the air by harmful substances such as gases, particles, and biological molecules, which negatively affect human health and the environment. The rise in air pollution is mainly caused by fossil fuel combustion, industrial emissions, vehicle exhaust, and agricultural activities. Cinqair (Cinqaero) helps mitigate the effects of air pollution by improving lung function and reducing inflammation, enhancing overall respiratory health and alleviating strain on healthcare systems often worsened by environmental pollutants. For example, in May 2025, the U.S. Environmental Protection Agency (EPA) reported that roughly 66 million tons of pollutants were released into the U.S. atmosphere in 2023. Therefore, increasing air pollution is driving the growth of the Cinqair (Cinqaero) market.

The rising prevalence of asthma is also expected to propel the growth of the Cinqair (Cinqaero) market. Asthma results from a combination of genetic and environmental factors, including family history, allergies, childhood respiratory infections, air pollution, and exposure to triggers such as pollen, dust mites, and tobacco smoke. Cinqair (Cinqaero) benefits asthma patients by targeting and inhibiting interleukin-5 (IL-5), a key protein involved in eosinophilic asthma inflammation, thereby reducing airway inflammation, improving lung function, and decreasing asthma exacerbations caused by allergens or environmental factors like air pollution. For instance, in July 2024, the American Lung Association reported that Black individuals had a current asthma rate of 10.3% in 2022, 44% higher than the 8.4% rate among white individuals, while adult asthma prevalence in 2023 varied from 7.1% in Mississippi to 14.1% in Puerto Rico. Therefore, the rising prevalence of asthma is driving the growth of the Cinqair (Cinqaero) market.

The growing demand for biological products is also expected to support the growth of the Cinqair (Cinqaero) market. Biological products are complex pharmaceuticals derived from living organisms and are used to diagnose, prevent, treat, or cure diseases. The rise in demand for biologics is driven by environmental concerns, greater consumer awareness, and the need for effective, sustainable alternatives to synthetic drugs. Biologics such as Cinqair (Cinqaero) target specific immune components like interleukin-5 (IL-5), which play a central role in eosinophilic asthma, reducing airway inflammation and improving respiratory function, particularly in patients whose asthma is triggered by environmental factors. For example, in August 2025, the Assistant Secretary for Planning and Evaluation reported that net revenue for biosimilars can range from a USD 33.5 million loss in smaller markets to USD 9.5 billion in larger ones, with proposed regulatory changes - including universal interchangeability, a global comparator, and removal of comparative efficacy studies - expected to cut development costs and increase lifetime revenues by USD 2 billion, USD 13.5 million, and USD 84 million, respectively. Therefore, the growing demand for biological products is driving the growth of the Cinqair (Cinqaero) market.

Major companies operating in the cinqair or cinqaero market are Teva Pharmaceuticals.

North America was the largest region in the cinqair or cinqaero market in 2025. Europe is expected to be the fastest-growing region in the forecast period. The regions covered in the cinqair or cinqaero market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the cinqair or cinqaero market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Tariffs have influenced the cinqair or cinqaero market by increasing costs for monoclonal antibody production inputs and sterile infusion supplies. Hospital and specialty clinic segments are most affected. Regions dependent on imported biologics face procurement challenges. At the same time, tariffs are supporting localized biologic manufacturing. This strengthens long-term supply resilience.

The cinqair or cinqaero market research report is one of a series of new reports that provides cinqair or cinqaero market statistics, including cinqair or cinqaero industry global market size, regional shares, competitors with a cinqair or cinqaero market share, detailed cinqair or cinqaero market segments, market trends and opportunities, and any further data you may need to thrive in the cinqair or cinqaero industry. This cinqair or cinqaero market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Cinqair (also known as Cinqaero) is reslizumab, a humanized monoclonal antibody primarily used to treat severe eosinophilic asthma in adults. It works by targeting and inhibiting interleukin-5 (IL-5), a key regulator of eosinophil production, thereby reducing eosinophil levels and inflammation in the body.

The main clinical indication for Cinqair/Cinqaero is severe eosinophilic asthma, a subtype of asthma characterized by elevated eosinophil levels, which contribute to airway inflammation. It is applicable for children, adults, and teenagers, and is used by hospitals, clinics, ambulatory care centers, and home care providers.

The cinqair or cinqaero market consists of sales of reslizumab in forms such as intravenous solutions, single-use vials, and pre-mixed infusions. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.